HALO: Record revenue, robust pipeline, and new platforms position for sustained royalty growth
Expansion into China and rapid AI adoption are driving operational gains and new partnerships. Record Q2 revenue and a diversified royalty base support strong long-term guidance, while new platforms like Hypercon and Surf Bio are set to expand future royalty streams.Based on Halozyme Therapeutics…
Expansion into China and rapid AI adoption are driving operational gains and new partnerships. Based on Halozyme Therapeutics…